Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

Keytruda is the world's bestselling drug ... "We now see a modest top-line sales growth of 2.1% Y/Y in 2025, after sales rose 7% Y/Y in 2024," said analyst Sel Hardy in a note to clients.

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Three companies that posted quarterly earnings yesterday are now on sale. PayPal (PYPL), Pfizer (PFE), and Merck (MRK) fell after disappointing investors. PayPal posted revenue of $8.4 billion (+5% ...

and tremelimumab have failed to score the big trial wins seen with Merck & Co's rival Keytruda (pembrolizumab). For now it remains to be seen whether this will develop into something serious ...

VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Guanajuato Silver Company Ltd. (the "Company" or "GSilver") is pleased to announce that a new National Instrument ("NI" ...